FDA Drug Recalls
557 recalls, newest first
Class II · Moderate risk Terminated Dec 30, 2024
Reason Presence of Foreign Tablets/Capsules: A Paracetamol 500 mg tablet was found in a 1000-count bottle of Metformin HCL ER Tablets USP, 500 mg.
Class II · Moderate risk Ongoing Dec 30, 2024
Reason CGMP Deviations; Presence of N-nitroso-duloxetine impurity above recommended interim limit.
Class II · Moderate risk Ongoing Dec 30, 2024
Reason CGMP Deviations; Presence of N-nitroso-duloxetine impurity above recommended interim limit.
Class II · Moderate risk Ongoing Dec 30, 2024
Reason CGMP Deviations; Presence of N-nitroso-duloxetine impurity above recommended interim limit.
Class II · Moderate risk Ongoing Dec 27, 2024
Reason Presence of Particulate Matter: A market complaint was received of a glass piece in the vial.
Class I · High risk Ongoing Dec 23, 2024
Reason Failed Tablet/Capsule Specifications: Bottles shipped to the USA may contain empty capsules
Class I · High risk Ongoing Dec 23, 2024
Reason Failed Tablet/Capsule Specifications: Bottles shipped to the USA may contain empty capsules
Class II · Moderate risk Ongoing Dec 23, 2024
Reason CGMP Deviations; product intended for quarantine was inadvertently distributed
Class II · Moderate risk Terminated Dec 23, 2024
Reason Failed Impurities/Degradation Specifications: Out of specification results observed for the impurity compound B during stability testing.
Class II · Moderate risk Terminated Dec 23, 2024
Reason Failed Impurities/Degradation Specifications: Out of specification results observed for the impurity compound B during stability testing.
Class I · High risk Ongoing Dec 20, 2024
Reason Labeling: Not Elsewhere Classified: misleading label similar in appearance to the FDA-approved drug product Adrenalin¿ (epinephrine injection, USP)
Class II · Moderate risk Terminated Dec 20, 2024
Reason Failed Impurities/Degradation Specifications: Out of specifications result observed in the drug substance for impurity test during 3-month long term…
Class III · Low risk Ongoing Dec 19, 2024
Reason Failed Tablet/Capsule Specifications: Illegible product identification for the unit dose configuration only.
Class II · Moderate risk Terminated Dec 19, 2024
Reason Lack of Assurance of Sterility: The tamper-evident seal on several of the syringes are not attached upon receipt of shipment.
Class II · Moderate risk Terminated Dec 19, 2024
Reason Lack of Assurance of Sterility: The tamper-evident seal on several of the syringes are not attached upon receipt of shipment.
Class I · High risk Ongoing Dec 18, 2024
Reason Non-Sterility
Class II · Moderate risk Terminated Dec 18, 2024
Reason Failed Dissolution Specifications: Out of specification observed during the accelerated stability conditions for the 30 count bottles.
Class II · Moderate risk Ongoing Dec 18, 2024
Reason CGMP Deviations
Class III · Low risk Ongoing Dec 18, 2024
Reason LABELING: LABEL MIX-UP
Class III · Low risk Ongoing Dec 18, 2024
Reason LABELING: LABEL MIX-UP
Class II · Moderate risk Terminated Dec 17, 2024
Reason Failed Dissolution Specifications:
Class I · High risk Ongoing Dec 16, 2024
Reason Marketed without an Approved NDA/ANDA; FDA laboratory analysis confirmed product tainted with undeclared metformin and glyburide
Class II · Moderate risk Ongoing Dec 16, 2024
Reason Defective container: Unable to get the solution out of the bottle as the spike of the cap was lodged in the nozzle of the product bottle
Class III · Low risk Terminated Dec 16, 2024
Reason Failed Impurities/Degradation Specifications
Class II · Moderate risk Ongoing Dec 13, 2024
Reason Presence of Foreign Tablets/Capsules